The U.S. Food and Drug Administration has expanded the role of Mounjaro, now authorizing it to lower cardiovascular risk in people living with type 2 diabetes. This decision could reshape treatment plans, influence prescribing habits, and affect insurers’ coverage choices. Patients and clinicians alike are weighing the promise and the …